New efforts are being made in medical technology that could potentially help stop the spread of HIV sooner than we think.
In 2011 the new anti-AIDS pill, Truvada, produced by Gilead Sciences Inc. and approved by the Food and Drug Administration on July 16th, is one of the first pills on the market that is helping to reduce the spread of the HIV infection in both homosexuals and bisexuals.
Recently after more research and analysis, daily use of the pill also known as pre-exposure prophylaxis (PrEP), is said to prevent the HIV infection in anyone who is uninfected, including heterosexuals.
Dawn Smith will author a new comprehensive guideline sheet that will offer guidance and more explanation in correlation with the pill. The guidance, set to come out end of year, will note that the pill prevents HIV from establishing permanent infections as it enters the body.
However, the Center for Disease Control, strongly explains that this pill does not take the place of regular testing and prevention methods.
The number of people living with HIV infection in the United States is estimated that more than 1 million (1,178,350) adults and adolescents, says the CDC.